Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genetic Change”

4,162 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 4,162 results

Testing effectiveness (Phase 2)UnknownNCT05005468
What this trial is testing

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.

Who this might be right for
NSCLC
Shanghai Chest Hospital 61
Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Very early researchLooking for participantsNCT06565026
What this trial is testing

CS-206 in Patients With Sickle Cell Disease

Who this might be right for
Sickle Cell Disease
CorrectSequence Therapeutics Co., Ltd 5
Large-scale testing (Phase 3)UnknownNCT03203590
What this trial is testing

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Who this might be right for
2-year Disease-Free Survival
Sun Yat-sen University 590
Large-scale testing (Phase 3)UnknownNCT02001896
What this trial is testing

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Xinjiang Medical University 60
Not applicableLooking for participantsNCT03564561
What this trial is testing

Natural History of Pompe Disease

Who this might be right for
Glycogen Storage Disease Type II, Adult
Assistance Publique - Hôpitaux de Paris 20
Not applicableUnknownNCT05411276
What this trial is testing

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Who this might be right for
HER2 Mutant Non-small Cell Lung Cancer
Beijing Chest Hospital 15
Not applicableStudy completedNCT02431117
What this trial is testing

Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30

Who this might be right for
Down Syndrome
Chugai Pharmaceutical 43
Testing effectiveness (Phase 2)Ended earlyNCT04310397
What this trial is testing

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Who this might be right for
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)WithdrawnNCT02965417
What this trial is testing

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Who this might be right for
Metastatic Colorectal Cancer
Symphogen A/S
Testing effectiveness (Phase 2)Active Not RecruitingNCT05379946
What this trial is testing

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Who this might be right for
Solid Tumor
InventisBio Co., Ltd 92
Testing effectiveness (Phase 2)UnknownNCT03646968
What this trial is testing

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study

Who this might be right for
Non-Squamous Non Small Cell Lung Cancer
Yongchang Zhang 43
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Not applicableStudy completedNCT02380729
What this trial is testing

Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality

Who this might be right for
Genetic Diseases
Charite University, Berlin, Germany 200
Load More Results